Parker Waichman LLP

Opdivo, Yervoy, and Keytruda Retinal Detachment Lawsuit Lawyers

Parker Waichman LLP is investigating cases of retinal detachment complications MONTGOMERY COUNTY, MD. – July 21, 2017 (immune-oncologynews.com) The FDA is considering adding updated warning information to three cancer drugs to include information about potential eye injuries, according to a news report from immune-oncologynews.com. Three cancer drugs currently on the market could cause vision loss […]

Parker Waichman LLP is investigating cases of retinal detachment complications

MONTGOMERY COUNTY, MD. – July 21, 2017 (immune-oncologynews.com) The FDA is considering adding updated warning information to three cancer drugs to include information about potential eye injuries, according to a news report from immune-oncologynews.com.

Three cancer drugs currently on the market could cause vision loss and retinal detachment:

  • Opdivo (nivolumab)
  • Yervoy (ipilimumab)
  • Keytruda (pembrolizumab)

Retinal detachment while taking Opdivo, Yervoy or Keytruda

 

Opdivo and Yervoy are manufactured by Bristol-Myers Squibb, and Keytruda is manufactured by Merck. All three are approved to treat melanoma, although Yervoy and Keytruda have additional indications, including treatment of non-small cell lung cancer.

Opdivo and Keytruda are both programmed death receptor-1 blocking antibodies. Yervoy is a human cytotoxic T-lymphocyte antigen 4-blocking antibody. All three drugs, however, work to change the immune system’s response to cancer cells by manipulating the body’s T cells. All three drugs interfere with T cell function to allow these cells to attack cancer cells, thereby creating an immune defense against cancer within patients’ bodies.

While the drugs have seen success, the post-market information reveals a potential risk associated with all three, including vision loss and retinal detachment. A recently published study detailed a patient who took Yervoy and suffered vision loss in his left eye four months after treatment. The same patient also experienced intermittent vision loss in his right eye five months after treatment. The patient’s injuries were found to be immune-related adverse reactions (IrAR) to the drug.

This patient represents numerous reports of vision injuries associated with the drugs. In early 2017, the U.S. Food and Drug Administration (FDA) released a notice titled, “Potential Signals of Serious Risks/New Safety Information Identified by the FDA Adverse Event Reporting System.” Keytruda, Opdivo, and Yervoy were all on the report with the potential serious risks of “ocular toxicities including vision loss and retinal detachment.” At this time, however, the FDA has taken no further action, and the drug labels remain unchanged.

Currently, all three drugs’ labels contain information about a condition called uveitis, which causes inflammation of the eye. The Yervoy label also currently contains a Black Box warning, which is the strongest possible warning for a drug label, regarding severe and fatal immune-mediated adverse reactions. The warning says these reactions can involve any organ system, with the most common reactions being enterocolitis, hepatitis, dermatitis, neuropathy, and endocrinopathy.

Regarding new information about eye injuries, the FDA is “evaluating the need for regulatory action.” Should the FDA find that adverse event information and subsequent studies warrant additional warnings inside the drug labels, it will direct the two manufacturers to change their labels. The FDA will also communicate the new warning information, and the manufacturers could take the additional step of notifying doctors who prescribe therapy with the three drugs.

In the meantime, the manufacturers will continue monitoring the safety of the drugs, including reports of adverse events, and will update the FDA if they discover additional information related to the risks of eye injuries. Patients who use Opdivo, Yervoy, or Keytruda — or some combination of the three — are encouraged to monitor their own symptoms and talk to their doctors right away if they notice any changes in eyesight. Following the appropriate medical intervention, patients are encouraged to report their experiences to the FDA, the manufacturer(s), or both.

The FDA’s Adverse Event Reporting System is one key way the Administration tracks post-market information on prescription drugs. When numerous instances of one particular adverse event appear in the system, the FDA starts to analyze whether the drug label needs to be updated and whether patients and doctors need to be warned. Additional information regarding the Adverse Event Reporting System can be found at fda.gov.

Contact Parker Waichman LLP for Your Free Retinal Detachment Case Evaluation

If you or your family member has been taking a cancer medication and suffered retinal detachment, contact our firm today for your free consultation by filling out our online form or by calling 1-800-YOURLAWYER (1-800-968-7529).

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
Parker Waichman handled a slip and fall case for my husband - which was handled with the utmost professionalism. Speaking with the paralegal assigned to the case, Lynda Luckman, was an absolute pleasure. She was helpful from the inception of his case, up until receiving closing papers. She always knew exactly what the status of the case was and was always there to answer any and all questions we had. Her patience and kindness was exemplary. Brett Zekowski, the attorney on the case, was very attentive to our requests and delivered a result that we were very pleased with. We will certainly recommend Parker Waichman to anyone in need of legal assistance!
Audra Massimo
5 years ago
5 Star Reviews 150
Parker Waichman are the best. They are always there for you. Theh really care about you. Thank you Jorge peniche and Linda Ingber for helping me
Ramon Mella
4 years ago
5 Star Reviews 150
Tina Morace provided me excellent support throughout the application process. She provided me with valuable follow-up on questions and any actions needed on my part. You have a valued employee with Tina
Joe Sinopoli
2 months ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038